Skip to main content

Table 1 Demographic and clinical baseline characteristics

From: Atrophy of the putamen at time of clinical motor onset in Huntington’s disease: a 6-year follow-up study

  Premanifest HD Controls
Non-converters Converters Combined
Number of participants 9 20 29 28
Gender (male/female) 3/6 9/11 12/17 13/15
Age (years) 41.6 (6.5) 44.2 (8.7) 43.3 (8.0) 48.6 (7.9)
CAG repeat length 42.4 (1.8) 43.8 (2.6) 43.4 (2.4)
Disease burden score 286 (56.9) 352 (61.3)* 332 (66.6)
UHDRS - TMS 1.9 (1.8) 2.7 (1.3) 2.4 (1.5) 2.6 (2.4)
  1. Data is given in mean (standard deviation). Premanifest HD gene carriers were divided into non-converters with a Diagnostic Confidence Level (DCL) below 4 and converters who progressed to manifest HD rated as a DCL of 4. CAG: cytosine-adenine-guanine. UHDRS-TMS: Unified Huntington’s Disease Rating Scale – Total Motor Score. Disease burden score = age x (CAG length − 35.5) by Penney et al. [12]
  2. *Significantly different between converters and non-converters at p < 0.05
  3. Significantly different between controls and premanifest HD combined group at p < 0.05